Amgen Meets Analyst Forecasts as It Fights Off Biosimilar Rivals

(Bloomberg) -- Amgen Inc., maker of the blockbuster arthritis drug Enbrel, reported first-quarter earnings that were mostly in line with analysts’ expectations, even as the company attempts to figh...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.